BMO Capital Downgrades Regulus Therapeutics (RGLS) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
Go back to BMO Capital Downgrades Regulus Therapeutics (RGLS) to Market Perform
June 28, 2016 1:35 PM EDT
FBR Capital analyst Christopher James lowered his price target on Regulus Therapeutics (NASDAQ: RGLS) to $9.00 (from $30.00) following the FDA clinical hold on RG-101 but maintained a Buy rating.
James commented, "We are lowering our price target to $9 on shares of RGLS, following Regulus' announcement yesterday that the FDA has placed its... More
June 28, 2016 7:38 AM EDT
Chardan Capital Markets analyst Madhu Kumar lowered his price target on Regulus Therapeutics (NASDAQ: RGLS) 33% to $13.50 after the company announced the start of a clinical hold for RG-101 in the treatment of chronic hepatitis C virus (HCV).
Based upon the clinical hold, the firm now lowers their peak risk-adjusted RG-101 sales to $1.2 bn and NPV to $9.24... More
June 27, 2016 4:45 PM EDT
Regulus Therapeutics (NASDAQ: RGLS) shares resume trading, the stock is down over 50% in after-hours trading.
...
More
June 27, 2016 4:10 PM EDT
Regulus Therapeutics Inc. (Nasdaq: RGLS) received verbal notice from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug (IND) for RG-101 for the treatment of chronic hepatitis C virus (HCV) infection has been placed on... More
